PACB
Time to buy PACB?$1.47
+$0.00 (-0.00%)
2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
PACB ran from about $1.58 to $1.73 in early May after Q1 results beat on earnings and management backed 2026 revenue guidance, then faded back near $1.47 as traders weighed weak instrument demand against the new SPRQ-Nx product rollout.
The stock has the potential to go down if it loses $1.35, with a retrace toward $1.15 to $1.20 possible and the 52 week low at $0.85 back in play if momentum really breaks. Any soft Q2 setup, slower academic funding, or another analyst cut would accelerate the downside.
If PACB holds the $1.35 to $1.40 area and volume sticks, a push back toward $1.70 and then $1.90 is on the table as SPRQ-Nx shipments and consumables growth start to show up. Resistance at $1.55 is the first hurdle.
Analyst Ratings
Pacific Biosciences of California Inc. Earnings
We don't currently have information about Pacific Biosciences of California Inc.'s earnings.